Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10558158
• 负责人: Alan David Hutson
• 金额: $ 10.55万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10558158
• 关键词: Address; Atlas of Cancer Mortality in the United States; Bioconductor; Bioinformatics; Biostatistics Shared Resource; Cancer Center Support Grant; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Data Management Resources; Dependence; Drug Kinetics; Drug resistance; Fostering; Immunooncology; Infrastructure; Malignant Neoplasms; Methods; Multiomic Data; Productivity; Research; Research Personnel; Resistance; Resource Sharing; Resources; Translations; anti-cancer therapeutic; biobank; cancer therapy; combat; data harmonization; data integration; data repository; design; drug sensitivity; expectation; experience; high standard; improved; innovation; metabolomics; multidisciplinary; outreach; predictive marker; real time monitoring; resistance mechanism; response; translational oncology; translational study; tumor

This application is being submitted in response to PA-20-272 Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi- disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno- Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well- functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly- successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

本申请是根据PA-20-272提交的 项目摘要 虽然几种创新和创造性的抗癌疗法已经显示出有希望的结果，但一个重要的 扩大其临床应用将需要合作努力，以阐明耐药机制，利用 肿瘤敏感性，绘制癌症依赖性，发现新靶点，鉴定预测性生物标志物，评估 联合疗法，并开发实时监测方法。利用尖端的多功能 学科团队的方法，我们将支持NCI药物耐药性和敏感性网络（DRSN）， 了解和对抗肿瘤耐药性的机制，并利用肿瘤对抗癌药物的敏感性 治疗我们的战略是作为一个管理、沟通、协作和分析中心， 协调DRSN的网络范围的研究，重点是减少领域专业知识的障碍， DRSN调查人员的工作效率，保持数据协调和整合的高标准， 设计和实施严格的分析战略，并促进合作和支持 研究社区。 一个经验丰富的多学科团队已经成立，以实现五个具体目标：首先，我们将 提供一个集中的管理基础设施，以协调DRSN活动，建立在免疫， 肿瘤转化网络（IOTN）数据管理和资源共享中心（DMRC）的良好- 目前在NCI癌症研究中心的保护伞下协调网络研究的功能基础设施 登月计划。二是积极推进DRSN，促进跨联盟互动， 在那里，我们将利用IOTN DMRC在跨月球探测外展方面的可证明的经验， Bioconductor数十年来在社区范围内的参与记录。第三，我们将提供多学科 专业知识，以支持DRSN合作研究，利用四个罗斯韦尔公园CCSG的共享 资源：生物统计学，生物信息学，数据库和生物库，生物分析学，代谢组学和 药代动力学。我们的分析支持将配备专业的IT人员，并通过 经验丰富的抗癌治疗研究团队。第四，我们将开发创新的多组学数据 整合方法，以提高DRSN的研究能力，利用备受尊敬和高度- 成功的Bioconductor项目第五，我们将向更广泛的人传播DRSN中开发的资源。 社区，释放DRSN活动的全部潜力。综上所述，我们设想我们的CC，在接近 与DRSN组件的合作，将使我们能够进行高效和创新的 转化研究，以解决与抗癌治疗相关的显著未满足的需求，并实现 NCI癌症登月计划的期望和指导原则。